Department of Interventional Radiology, Yichang Central People's Hospital, First College of Clinical Medical Science, China Three Gorges University, 183 Yiling Avenue, Yichang, 443003, China.
BMC Cancer. 2023 Oct 12;23(1):970. doi: 10.1186/s12885-023-11350-y.
CalliSpheres® is a microsphere that is already widely used for primary liver cancer treatment; however, its application in colorectal cancer liver metastasis (CRLM) is limited. The current study aimed to investigate the efficacy of CalliSpheres® drug-eluting bead (DEB) transarterial chemoembolization (TACE) therapy versus (vs.) conventional cTACE therapy in treating refractory CRLM (RCRLM) patients.
Twenty-two RCRLM patients who underwent CalliSpheres® DEB-TACE therapy (n = 11) or cTACE therapy (n = 11) were retrospectively analyzed. Data on clinical response, progression-free survival (PFS) and overall survival (OS) were retrieved.
The objective response rate (36.4% vs. 18.2%, P = 0.338) and disease control rate (81.8% vs. 54.4%, P = 0.170) were both numerically (but not statistically) higher in the DEB-TACE group than in the cTACE group. Meanwhile, PFS was prolonged in the DEB-TACE group compared with the cTACE group [median: 12.0 (95% CI: 5.6-18.4) vs. 4.0 (95% CI: 0.9-7.1) months, P = 0.018]; OS was also longer in the DEB-TACE group compared with the cTACE group [median: 24.0 (95% CI: 18.3-29.7) vs. 14.0 (95% CI: 7.1-20.9) months, P = 0.040]. In addition, after adjustment by multivariate Cox analyses, DEB-TACE was superior to cTACE independently regarding PFS (HR: 0.110, 95% CI: 0.026-0.463, P = 0.003) and OS (HR: 0.126, 95% CI: 0.028-0.559, P = 0.006).
CalliSpheres® DEB-TACE therapy may prolong survival profile than cTACE therapy in RCRLM patients, while further validation is still needed.
CalliSpheres®是一种已广泛用于原发性肝癌治疗的微球，但在结直肠癌肝转移（CRLM）中的应用有限。本研究旨在探讨CalliSpheres®载药微球（DEB）肝动脉化疗栓塞术（TACE）与常规 cTACE 治疗难治性 CRLM（RCRLM）患者的疗效。
回顾性分析 22 例接受 CalliSpheres® DEB-TACE 治疗（n=11）或 cTACE 治疗（n=11）的 RCRLM 患者。检索临床反应、无进展生存期（PFS）和总生存期（OS）的数据。
DEB-TACE 组客观缓解率（36.4% vs. 18.2%，P=0.338）和疾病控制率（81.8% vs. 54.4%，P=0.170）均高于 cTACE 组，但无统计学差异。同时，DEB-TACE 组的 PFS 长于 cTACE 组[中位：12.0（95%CI：5.6-18.4）vs. 4.0（95%CI：0.9-7.1）个月，P=0.018]；OS 也长于 cTACE 组[中位：24.0（95%CI：18.3-29.7）vs. 14.0（95%CI：7.1-20.9）个月，P=0.040]。此外，经多变量 Cox 分析调整后，DEB-TACE 在 PFS（HR：0.110，95%CI：0.026-0.463，P=0.003）和 OS（HR：0.126，95%CI：0.028-0.559，P=0.006）方面均优于 cTACE。
在 RCRLM 患者中，CalliSpheres® DEB-TACE 治疗可能比 cTACE 治疗延长生存时间，但仍需进一步验证。
